Harnessing endogenous carbon monoxide for cancer-selective drug synthesis.

Endogenous carbon monoxide enables cancer-specific drug synthesis using a biocompatible palladium platform, producing cytotoxic agents that suppress tumor growth.

• Why it matters: Targeted drug delivery within living systems remains challenging, especially for exploiting disease-specific metabolites like CO, which is elevated in many cancers, to improve precision medicine.
• What they did: A novel albumin-palladacycle complex (APC) was developed to detect CO levels and catalyze the in situ synthesis of therapeutic phenanthridinone derivatives, shielding the catalyst from intracellular thiols.
• The result: This system effectively identifies elevated CO in cancer cells and produces cytotoxic agents that modestly inhibit cell growth, demonstrating a promising approach for disease-specific synthetic chemistry in vivo.